<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0708233967
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Quenfil
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        HYDROXYCHLOROQUINE SULFATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        200
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        65.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="(Avalon Pharma) Middle East Pharmaceutical Industries Co. Ltd" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            (Avalon Pharma) Middle East Pharmaceutical Industries Co. Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 437]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Middle East Pharmaceutical Industries Co Ltd Avalon Pharma
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Middle East Pharmaceutical Industries Co Ltd Avalon Pharma
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        P01BA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Quenfil contain a medicine called Hydroxychloroquine sulfate. Quenfil works by reducing inflammation in people with autoimmune diseases (this is where the body&rsquo;s immune system attacks itself by mistake). It can be used for: &bull; Rheumatoid arthritis (inflammation of the joints) &bull; Juvenile idiopathic arthritis (in children) &bull; Discoid and systemic lupus erythematosus (a disease of the skin or the internal organs) &bull; Skin problems which are sensitive to sunlight</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Quenfil if: &bull; You are allergic (hypersensitive) to: - Hydroxychloroquine sulfate - Other similar medicines such as quinolones and quinine - Any of the other ingredients of Quenfil (listed in section 6). Signs of allergic reaction include: a rash, swallowing or breathing problems, swelling of your lips, face, throat or tongue. &bull; You have an eye problem which affects the retina, the inside of the eye (maculopathy) or you get a change in eye colour or any other eye problem. &bull; You are pregnant, might become pregnant or think you may be pregnant (see،pregnancy and breast feeding below) &bull; Quenfil should not be used in children under 6 years of age or below 35kg. Do not take this medicine if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist before taking Quenfil. Warnings and precautions Talk to your doctor or pharmacist before taking Quenfil if: &bull; You have liver or kidney problems. &bull; You have serious stomach or gut problems. &bull; You are taking a drug called Tamoxifen, used to treat breast cancer &bull; You have any problems with your blood. You may have blood tests to check this. &bull; you have heart problems (signs include breathlessness and chest pain) which may require monitoring. &bull; you have any problems with your nervous system or brain. &bull; you have psoriasis (red scaly patches on the skin usually affecting the knees, elbows and scalp). &bull; you have had a bad reaction to quinine in the past. &bull; you have a genetic condition known as &lsquo;glucose-6- dehydrogenase deficiency&rsquo;. &bull; you have a rare illness called &lsquo;porphyria&rsquo; which affects your metabolism. &bull; Hydroxychloroquine sulfate can cause lowering of the blood glucose level. Please ask your doctor to inform you of signs and symptoms of low blood glucose levels. A check of the blood glucose level may be necessary. Before treatment with Quenfil &bull; Before you take this medicine you should have your eyes examined. &bull; This testing should be repeated at least every 12 months whilst taking Quenfil. &bull; If you are over 65, need to take a high dose (2 tablets a day) or have kidney problems then this examination should be performed more often. If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before taking Quenfil. Children Quenfil should not be used in children under 6 years of age or below 35kg. small children are particularly sensitive to the toxic effect of quinolones. so Quenfil should be kept out of the reach of children. Other medicines and Quenfil Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. The following medicines may increase the chance of you getting side effects when taken with Quenfil: &bull; Some antibiotics used for infections (such as azithromycin, clarithromycin, erythromycin, gentamicin, neomycin or tobramycin). Taking azithromycin, clarithromycin, or erythromycin at the same time as hydroxychloroquine may increase the chance of you getting side effects that affect your heart. &bull; Cimetidine &ndash; used for stomach ulcers. &bull; Neostigmine and pyridostigmine &ndash; used for muscle weakness (myasthenia gravis). &bull; Medicines that may affect the kidneys or liver. &bull; Medicines that affect the skin or the eyes. &bull; Halofantrine, mefloquine, moxi&not;floxacin &ndash; used for malaria. &bull; Some medicines used to treat arrhythmias (such as amiodarone). &bull; Moxifloxacin - used to treat infections &bull; Medicines used for psychiatric disorders (such as amisulpride, quetiapine, risperidone). The following medicines can change the way Quenfil works or Quenfil may affect the way some of these medicines work: &bull; Digoxin &ndash; used for heart problems. &bull; Medicines for epilepsy &bull; Medicines for diabetes (such as insulin or metformin). &bull; Antacids &ndash; used for heartburn or indigestion. You should leave a gap of at least 4 hours between taking these medicines and Quenfil &bull; Rabies vaccine. &bull; Ciclosporin &bull; Praziquantel &bull; Agalsidase Pregnancy, breast-feeding. Do not take Quenfil if: &bull; You are pregnant, might become pregnant or think you may be pregnant &bull; You are breast-feeding or planning to breast-feed. This is because small amounts may pass into mothers&rsquo; milk If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Driving and using machines You may get eye problems while taking this medicine. If this happens, do not drive or use any tools or machines, and tell your doctor straight away. Quenfil contains lactose This medicine contains lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as described in this leaflet or as your doctor or pharmacist have told you. Check with your doctor or pharmacist if you are not sure. &bull; The doctor will work out the dose depending on your body weight. If you feel the effect of your medicine is too weak or too strong, do not change the dose yourself, but ask your doctor. &bull; If you have been taking this medicine for rheumatoid arthritis for a long time (more than 6 months) and you do not feel that it is helping you, see your doctor. This is because the treatment may need to be stopped. The recommended dose is: Adults (including the elderly) &bull; One or two tablets each day. Children and adolescents &bull; One tablet each day. &bull; This medicine is only suitable for children who weigh more than 35 kg (around 5.5 stones). It may take several weeks before you notice the benefit of taking Quenfil. Method of administration &bull; Take this medicine by mouth. &bull; Swallow the tablets whole with a meal or a glass of milk. Do not crush or chew your tablets. &bull; If you are taking this medicine for skin problems that are sensitive to sunlight, only take Quenfil during periods of high exposure to light. If you take more Quenfil than you should &bull; If you take more Quenfil han you should, tell your doctor or go to a hospital casualty department straight away. Take the medicine pack with you. This is so the doctor knows what you have taken. &bull; The following effects may happen: headache, problems with your eyesight, fall in blood pressure, convulsions (fits), heart problems , followed by sudden severe breathing problems and possibly heart attack. Overdose of Quenfil may have a fatal outcome &bull; Young children and babies are particularly at risk if they accidentally take Quenfil. Take the child to hospital straight away. If you forget to take Quenfil If you forget a dose, take it as soon as your remember it. However, if it is nearly time for the next dose, skip the missed dose. Do not take a double dose to make up for a forgotten tablet. If you stop taking Quenfil Keep taking Quenfil until your doctor tells you to stop. Do not stop taking Quenfil just because you feel better. If you stop, your illness may get worse again. If you have any further questions on the use of this medicine, ask your doctor, nurse, or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Possible side effects: Stop taking Quenfil and see a doctor or go to a hospital straight away if: &bull; You have an allergic reaction. The signs may include: a red or lumpy rash, swallowing or breathing problems, swelling of the eyelids, lips, face, throat or tongue. Stop taking Quenfil and see a doctor straight away if you notice any of the following serious side effects &ndash; you may need urgent medical treatment: &bull; A small number of people being treated with Quenfil have had thoughts of harming or killing themselves. If at any time you have these thoughts, immediately contact your doctor &bull; You have any eye problems. This includes changes in the colour of your eye and problems with your eyesight such as blurring, sensitivity to light or the way you see colour. &bull; You have any muscle weakness, cramps, stiffness or spasms or changes in sensation such as tingling. &bull; If you take this medicine for a long time, your doctor will occasionally check your muscles and tendons to make sure they are working properly. &bull; Severe skin reactions such as blistering, widespread scaly skin, pus-filled spots together with a high temperature. &bull; Blistering or peeling of the skin around the lips, eyes, mouth, nose and genitals, flu-like symptoms and fever. This could be a condition called StevensJohnson Syndrome. &bull; Multiple skin lesions, itching of the skin, joint aches, fever and a general ill feeling. This could be a condition called Toxic Epidermal Necrolysis. &bull; You may get infections more easily than usual. This could be due to bone marrow depression or a blood disorder called &lsquo;agranulocytosis&rsquo; &bull; You may bruise more easily than usual. This could be due to a blood problem called &lsquo;thrombocytopenia&rsquo; &bull; You feel tired, faint or dizzy and have pale skin. These could be symptoms of something called &lsquo;anaemia&rsquo;. &bull; You feel weak, short of breath, bruise more easily than usual and get infections more easily than usual. These could be symptoms of something called &lsquo;aplastic anaemia&rsquo;. &bull; You notice yellowing or your skin or your eyes or your urine becomes darker in colour. This could be a liver problem, such as jaundice or hepatitis. Tell your doctor or pharmacist if any of the following side effects get serious or lasts longer than a few days: &bull; Skin rashes, itching, changes in the colour of your skin or the inside of your nose or mouth &bull; Psoriasis (red scaly patches on the skin usually affecting the knees, elbows and scalp) &bull; Hair loss or loss of hair colour &bull; Feeling or being sick, diarrhoea, loss of appetite (anorexia) or stomach pain &bull; Feeling nervous, ringing in the ear (tinnitus), hearing loss, headache, fits, balance problems (vertigo) or feeling dizzy, mental problems (such as delusions, hallucinations and changes in mood) &bull; Weakening of the heart muscle (cardiomyopathy) resulting in difficulty in breathing, coughing, high blood pressure, swelling, increased heart rate, low amount of urine. &bull; You may get infections more easily than usual. This could be due to bone marrow depression or a blood disorder called &lsquo;agranulocytosis&rsquo; &bull; Symptoms of a condition called &lsquo;porphyria&rsquo; which may include stomach pain, being sick, fits, blisters, itching &bull; Symptoms of lowering of the blood glucose level (hypoglycaemia). You may feel a sense of nervousness, shaky or sweaty &bull; Trembling, muscle spasm or irregular jerky movements Tests Your doctor may monitor: &bull; Periodic blood counts are advised for patients on long-term therapy and Quenfil should be discontinued if abnormalities occur &bull; A blood test may show changes in the way the liver is working and occasionally the liver may stop working &bull; Your heart&rsquo;s electrical activity using an ECG (electrocardiogram) machine &bull; Your muscle function and tendon reflexes Reporting of side effects If you get any side effects, talk to your doctor, nurse, or pharmacist. This includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep this medicine out of the sight and reach of children. &bull; Do not use this medicine after the expiry date which is stated on the carton and label after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month. &bull; Store below 30&deg;C &bull; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is: Hydroxychloroquine sulfate The other ingredients are: Lactose monohydrate (Pharmatose 200), Maize starch, Povidone K 30 (Kollidone k 30), Magnesium Stearate (Parteck LUB MST), Opadry White (OY-L-28900)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Quenfil tablets is a White, round shaped biconvex filmcoated tablet plain 
on both sides.
Quenfil tablets is available in packs with 6 blisters (10 tablets / blister).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Middle East Pharmaceutical Industries Co Ltd (Avalon Pharma) P.O.Box 4180 Riyadh 11491 2nd Industrial City, Riyadh, Kingdom of Saudi Arabia Tel: +966 (11) 2653948 -2653427 Fax: +966 (11) 2654723</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was approved in [01/2023]
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي كوينفل على دواء يُسمى سلفات الهيدروكسي كلوروكين. يعمل كوينفل على تخفيف االلتهاب لدى األشخاص المصابين بأمراض المناعة الذاتية )حيث يهاجم جهاز المناعة في الجسم نفسه عن طريق الخطأ(. يمكن استخدام هذا الدواء في الحاالت التالية: &bull; التهاب المفاصل الروماتويدي )التهاب المفاصل(. &bull; االلتهاب المفصلي الروماتويدي اليفعي )لدى األطفال(. ُ ْر ِصيَّة والمجموعية )مرض يصيب البشرة أو األعضاء الداخلية(. ٌ الق ٌ ُ الح َم ِاميَّة َة ْب ِ &bull; الذئ &bull; مشاكل في البشرة الحساسة لضوء الشمس.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ال تتناول أقراص كوينفل في الحاالت التالية: ٍ من: ّ &bull; إذا كنت تعاني من حساسية )فرط التحسس( تجاه أي - سلفات الهيدروكسي كلوروكين. - األدوية األخرى المشابهة مثل الكينولونات والكينين. ّ - المكونات األخرى لهذا الدواء )المذكورة في القسم 6(. تتضمن عالمات رد الفعل التحسسي الطفح الجلدي ومشاكل في البلع أو التنفس وتورم الشفتين أو الوجه أو الحلق أو اللسان. &bull; إذا كانت لديك مشكلة في العين تؤثر على شبكية العين أو على داخل العين )اعتالل البقعة( أو إذا حدث تغير في لون العين أو أي مشكلة أخرى بالعين. ِ &bull; إذا كنت حامًاًل أو قد تصبحين حامًاًل، أو تعتقدين أنك قد تكونين حامًاًل )راجعي &raquo;الحمل والرضاعة الطبيعية&laquo; أدناه(. ُستخدم كوينفل بالنسبة لألطفال األقل من عمر 6 سنوات أو األقل من وزن &bull; يجب أال ي 35 كلغ. ً ال تتناول هذا الدواء إذا كان أي مما سبق ينطبق عليك. إذا لم تكن متأكدا تحدث إلى طبيبك أو إلى الصيدلي قبل أن تتناول كوينفل. التحذيرات واالحتياطات تحدث إلى طبيبك أو الصيدلي قبل تناول كوينفل أقراص مغلفة إذا: َ &bull; كنت تعاني من مشاكل في الكبد أو الكلى. َ &bull; كنت تعاني من مشاكل خطيرة في المعدة أو األمعاء. ُستعمل لعالج السرطان ُ ّسمى تاموكسيفين، ي &bull; كنت تأخذ دواء ي َ &bull; كنت تعاني من أي مشاكل في الدم. قد تقوم بإجراء فحوصات دم للتحقق من ذلك. َ &bull; كنت تعاني من مشاكل في القلب )تشمل العالمات ضيق التنفس وألم في الصدر( والتي قد تحتاج إلى مراقبة. َ &bull; كنت تعاني من أي مشاكل في الجهاز العصبي أو الدماغ. َ &bull; كنت تعاني من الصدفية )بقع حمراء متقشرة على الجلد تصيب عادة الركبتين والمرفقين وفروة الرأس(. َ &bull; كنت قد عانيت من رد فعل سيىء تجاه مادة الكينين في الماضي. ُ ِ عرف باسم &raquo;عوز سداسي فوسفات الجلوكوز النازع للهيدروجين&laquo;. &bull; لديك حالة وراثية ت &bull; لديك مرض نادر يسمى &raquo;البورفيريا&laquo; الذي يؤثر على عملية التمثيل الغذائي لديك. ً &bull; يمكن للهيدروكسي كلوروكين أن يسبب انخفاضا في مستويات سكر الدم. يرجى أن تطلب من طبيبك أن يخبرك بعالمات وأعراض انخفاض مستويات السكر في الدم. قد يكون من الضروري ان تقوم بإجراء فحص لمستوى سكر الدم. قبل العالج بـ كوينفل &bull; قبل أن تتناول هذا الدواء، يجب إجراء فحص لعينيك. &bull; يجب تكرار هذا الفحص كل 12 ً شهرا على األقل أثناء تناول كوينفل. &bull; إذ كان عمرك يزيد عن 65 ً عاما وتحتاج إلى تناول جرعة كبيرة )قرصان يوميًّا( أو كنت ً تعاني من مشاكل في الكلى، يجب إجراء هذا الفحص بصورة أكثر تواترا. ً إذا لم تكن متأكدا مما إذا كان أي مما سبق ينطبق عليك، فتحدث إلى طبيبك أو الصيدلي قبل تناول كوينفل. األطفال ُستخدم كوينفل أقراص مغلفة لألطفال الذين عمرهم أقل من 6 سنوات أو األقل من يجب أال ي وزن 35 كلغ، فاألطفال الصغار حساسون بشكل خاص للتأثير السام للكوينولونات. لذلك ً يجب االحتفاظ بـ كوينفل بعيدا عن متناول األطفال. األدوية األخرى وكوينفل َ أخبر طبيبك أو الصيدلي إذا كنت ً تتناول أو قد تناولت مؤخرا أو قد تتناول أي أدوية أخرى. قد تتسبب األدوية التالية في زيادة فرصة التعرض لآلثار الجانبية عند تناولها مع كوينفل: &bull; بعض المضادات الحيوية المستخدمة في حاالت العدوى )مثل أزيثروميسين ، كالريثروميسين ، إريثروميسين ، جنتاميسين أو نيومايسين أو توبراميسين(. استخدام أزيثروميسين أو كالريثروميسين أو إريثروميسين مع هيدروكسي كلوروكين في نفس الوقت قد يزيد من فرصة إصابتك بآثار جانبية تؤثر على القلب. ُستخدم في عالج قرحة المعدة. &bull; سيميتيدين - ي ُستخدمان في عالج ضعف العضالت )الوهن العضلي &bull; نيوستيجمين وبيريدوستيغمين - ي الوبيل(. &bull; األدوية التي قد تؤثر على الكلى أو الكبد. ّر على الجلد أو العينين &bull; األدوية التي تؤث &bull; األدوية المستعملة لعالج المالريا )مثل الهالوفانتين، الميفلوكين، الموكسيفلوكساسين( &bull; بعض األدوية المستخدمة في عالج عدم انتظام ضربات القلب )مثل األميودارون(. &bull; موكسيفلوكساسين- يستخدم لعالج حاالت العدوى &bull; األدوية المستخدمة لالضطرابات النفسية )مثل أميسولبرايد ، كويتيابين ، ريسبيريدون( يمكن لألدوية التالية أن تغير طريقة عمل كوينفل أو قد يؤثر كوينفل على طريقة عمل بعض هذه األدوية: ُستخدم لمشاكل القلب. &bull; الديجوكسين - ي &bull; أدوية الصرع &bull; األدوية المستخدمة في عالج مرض السكري )مثل األنسولين أو الميتفورمين(. &bull; مضادات الحموضة &ndash; المستخدمة في عالج حرقة المعدة أو عسر الهضم. يجب أن تكون هناك مدة زمنية ال تقل عن 4 ساعات بين تناول هذه األدوية و كوينفل. &bull; لقاح داء الكلب. &bull; السيكلوسبورين &bull; برازيكوانتيل &bull; اجالسيداز الحمل والرضاعة الطبيعية. ال تأخذي كوينفل إذا: ً ً ِ أو تعتقدين نفسك حامال ً أو قد تصبحين حامال ِ &bull; كنت حامال ُ ّ رضعين أو تنوين اإلرضاع، ألن كميّات صغيرة من الدواء قد تعبر إلى حليب األم. ِ &bull; كنت ت ِ إذا كنت حامًاًل أو تقومين بالرضاعة الطبيعية، أو تعتقدين أنك حامل أو تخططين إلنجاب ِ طفل، يجب عليك سؤال طبيبك أو الصيدلي للحصول على المشورة قبل تناول هذا الدواء. القيادة واستخدام اآلالت قد تعاني من مشاكل في العينين أثناء تناول هذا الدواء. إذا حدث ذلك فال تقم بالقيادة أو استخدام أي أدوات أو ماكينات وأبلغ طبيبك على الفور. يحتوي كوينفل على الالكتوز ّ يحتوي هذا الدواء على الالكتوز. إذا أخبرك طبيبك أنك تعاني من عدم تحمل بعض السكريات، فاتصل بطبيبك قبل تناول هذا المنتج الطبي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول هذا الدواء تماما كما هو موصوف في هذه النشرة أو كما أخبرك طبيبك أو الصيدلي. ً استشر طبيبك أو الصيدلي إذا لم تكن متأكدا. َ &bull; سيحدد لك الطبيب الجرعة حسب وزن جسمك. إذا كنت ًّ تشعر أن تأثير الدواء قوي جدا أو ًّ ضعيف جدا، فال تغير الجرعة بنفسك ولكن استشر طبيبك. َ &bull; إذا كنت تتناول هذا الدواء الخاص لعالج التهاب المفاصل الروماتويدي لفترة طويلة )أكثر من 6 أشهر( وتشعر أنه ال يساعدك فاستشر طبيبك؛ ألن هذا العالج قد يحتاج أن يتم إيقافه. الجرعة الموصى بها هي: البالغون )بما في ذلك كبار السن( &bull; قرص واحد أو قرصان يوميًّا. األطفال والمراهقون &bull; قرص واحد يوميًّا. &bull; هذا الدواء مناسب لألطفال الذين يزيد وزنهم عن 35 كلغ )حوالي 5.5 أحجار(. قد يستغرق األمر عدة أسابيع قبل أن تالحظ فائدة تناول كوينفل أقراص مغلفة. طريقة تناول الدواء &bull; تناول هذا الدواء عن طريق الفم. &bull; ابتلع األقراص بالكامل مع الطعام أو مع كوب من الحليب. ال تسحق األقراص أو تمضغها. َ &bull; إذا كنت تتناول هذا الدواء لعالج مشاكل حساسة ألشعة الشمس في الجلد، فتناول كوينفل خالل فترات التعرض العالي للضوء فقط. إذا تناولت كوينفل أكثر مما يجب &bull; إذا تناولت كوينفل أقراص مغلفة أكثر مما يجب، فاستشر طبيبك أو توجه إلى قسم الطوارئ في المستشفى على الفور. خذ علبة الدواء معك حتى يعرف الطبيب ما تناولته. &bull; قد تشعر باألعراض التالية: صداع، مشاكل في الرؤية، هبوط في ضغط الدم، تشنجات )نوبات(، مشاكل في القلب ، تليها مشاكل تنفسية حادة مفاجئة وربما نوبة قلبية. قد تسبّب الجرعة المفرطة من كوينفل الى الوفاة. &bull; يتعرض األطفال الصغار والرضع للخطر بشكل كبير عند تناول كوينفل عن طريق الخطأ. اصطحب الطفل إلى المستشفى على الفور. إذا نسيت تناول كوينفل إذا نسيت إحدى الجرعات، فعليك أن تتناولها بمجرد أن تتذكرها، ولكن إذا كان الوقت قد ًا لتناول الجرعة التالية، فتجاوز الجرعة الفائتة. ال تأخذ جرعة مضاعفة لتعويض حان تقريب الجرعة المنسية. إذا توقفت عن تناول كوينفل ال تتوقف عن تناول كوينفل ما لم يخبرك طبيبك بذلك. ال تتوقف عن تناول كوينفل لمجرد أنك تشعر بتحسن. إذا توقفت عن تناول الدواء فقد يتفاقم مرضك مرة أخرى. إذا كانت لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو ممرضتك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع األدوية قد يسبب هذا الدواء بعض اآلثار الجانبية، على الرغم من أن ذلك ال يحدث مع الجميع. اآلثار الجانبية المحتملة: توقف عن تناول كوينفل أقراص مغلفة وقم بزيارة طبيبك أو توجه إلى المستشفى على الفور، ٍ مما يلي: ّ عند حدوث أي ً &bull; تعرضت لرد فعل تحسسي. قد تتضمن تلك األعراض: طفحا جلديًّا أحمر أو متكتًاًل أو صعوبة في البلع أو في التنفس، انتفاخ الجفون أو الشفتين أو الوجه أو الحلق أو اللسان. توقف عن تناول كوينفل وقم بزيارة طبيبك على الفور إذا الحظت أيًّا من اآلثار الجانبية الخطيرة التالية - فقد تحتاج إلى عالج طبي عاجل: ً &bull; تراود عددا قليال من األشخاص المعالجين كوينفل أفكار إللحاق األذى بأنفسهم أو لالنتحار. ّ إذا راودتك هذه األفكار في أي وقت، اتصل بطبيبك على الفور. &bull; حدوث مشاكل في العينين. يتضمن ذلك تغيير لون عينيك ومشاكل في بصرك مثل عدم وضوح الرؤية أو الحساسية للضوء أو تغير في الطريقة التي ترى بها األلوان. &bull; شعور بضعف في العضالت أو تشنجات أو تصلب أو تغيرات في اإلحساس مثل الوخز. َ &bull; إذا كنت قد تناولت هذا الدواء لفترة طويلة، فسيقوم طبيبك من وقت آلخر بفحص عضالتك وأوتارك للتأكد من أنها تعمل بشكل صحيح. &bull; رد فعل جلدي شديد مثل تقرحات أو تقشر الجلد المنتشر على نطاق واسع، والبقع المليئة بالصديد مع ارتفاع درجة الحرارة. &bull; تقرحات أو تقشر الجلد حول الشفتين والعينين والفم واألنف واألعضاء التناسلية وأعراض تشبه أعراض األنفلونزا والحمى. قد تنتج هذه األعراض عن حالة تسمى متالزمة ستيفنز جونسون &bull; آفات جلديّ ّ ة متعددة، حكة جلديّة، ألم في المفاصل، حمى وشعور عام بالمرض. يمكن أن ُ ّسم ّ ى النكروز الجلدي السام. تكون هذه حالة ت ُصاب بحاالت عدوى بسهولة أكثر من العادة. يمكن أن يكون السبب خمود نخاع العظم &bull; قد ت ُ ّسمى &raquo;ندرة المحببات&laquo; أو اضطراب في الدم ي &bull; قد تتعرض للكدمات بسهولة أكبر من المعتاد. قد يعود ذلك إلى مشكلة في الدم تسمى &raquo;قلة الصفيحات&laquo;. &bull; قد تشعر بالتعب أو اإلغماء أو الدوار وبشرتك شاحبة. يمكن أن تكون هذه أعراض لشيء يسمى &raquo;فقر الدم&laquo;. &bull; قد تشعر بالضعف وضيق التنفس وتصاب بالكدمات بسهولة أكبر من المعتاد وتصاب بالعدوى بسهولة أكبر من المعتاد. يمكن أن تكون هذه أعراض لشيء يسمى &raquo;فقر الدم الالتنسجي&laquo;. &bull; الحظت اصفرار بشرتك أو عينيك أو لون بولك أغمق. قد ينتج ذلك عن مشاكل في الكبد، مثل اليرقان أو التهاب الكبد. ٌّ أخبر طبيبك أو الصيدلي إذا تفاقمت أي من اآلثار الجانبية التالية أو استمرت أكثر من بضعة أيام: ّ &bull; طفح جلدي ّ ، حكة، تغييرات في لون جلدك أو داخل أنفك أو فمك. &bull; الصدفية )بقع حمراء متقشرة على الجلد تصيب عادة الركبتين والمرفقين وفروة الرأس(. &bull; تساقط الشعر أو فقدان لون الشعر. &bull; غثيان أو تقيّؤ، إسهال، فقدان الشهيّة )قهم( أو ألم في المعدة. &bull; الشعور بعصبيّة، طنين في األذن، فقدان السمع، صداع، نوبات، مشاكل في التوازن )دوخة( أو الشعور بدوار، مشاكل عقليّة )مثل األوهام أو الهلوسات أو تغييرات في المزاج(. &bull; ضعف عضلة القلب )اعتالل عضلة القلب( مما يؤدي إلى صعوبة التنفس، والسعال، وارتفاع ضغط الدم، والتورم، وزيادة معدل ضربات القلب، وانخفاض كمية البول. ُصاب بحاالت عدوى بسهولة أكثر من العادة. يمكن أن يكون السبب خمود نخاع العظم. &bull; قد ت &bull; أعراض حالة تسمى &raquo;البورفيريا&laquo; والتي قد تشمل آالم المعدة، والغثيان، والنوبات، والبثور، والحكة. &bull; انخفاض مستويات السكر في الدم )نقص سكر الدم(. قد تشعر بإحساس بالعصبية أو الرجفة أو التعرق. ّجة غير منتظمة. ّج عضلي، أو حركات متشن &bull; رجفة، تشن الفحوصات قد يراقب طبيبك: &bull; نشاط القلب الكهربائي باستخدام جهاز تخطيط كهربية القلب )تخطيط كهربية القلب( &bull; وظيفة العضالت وردود األوتار ُنصح بإجراء تعدادات دوريّة للدم للمرضى المعالجين ب كوينفل أقراص مغلفة لوقت &bull; ي طويل ويجب إيقاف العالج كوينفل في حال كانت نتائج الفحوصات غير طبيعيّة. ّف الكبد عن العمل. ًا قد يتوق ُظهر فحص الدم تغييرات في طريقة عمل الكبد وأحيان &bull; قد ي اإلبالغ عن اآلثار الجانبية ٍ من اآلثار الجانبية، استشر طبيبك أو الممرضة أو الصيدلي. ويشمل هذا أي ّ إذا تعرضت ألي ُ آثار جانبية محتملة غير م َدرجة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ هذا الدواء بعيدا عن متناول ومرأى األطفال. &bull; ي &bull; ال تستخدم الدواء بعد تاريخ االنتهاء الموضح على العبوة بعد كلمة EXP. يشير تاريخ االنتهاء إلى اليوم األخير من ذلك الشهر. ُحفظ في درجة حرارة أقل من 30 درجة مئوية. &bull; ي &bull; يجب عدم التخلص من األدوية في مياه الصرف الصحي أو في قمامة المنزل. اسأل ُ ْد بحاجة إلى استخدامها؛ ألن هذه التدابير الصيدلي عن كيفية التخلص من األدوية التي لم تَع تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي: سلفات الهيدروكسي كلوروكين المكونات األخرى هي: الكتوز أحادي النميّه، نشا الذرة، بوفيدون 30K، ستيرات المغنيسيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>كوينفل أقراص مغلفة هي أقراص بيضاء، مستديرة الشكل، ثنائية التحدب، مغطاة، خالية من النقوش على كال الجانبين. كوينفل متاح في عبوات تحتوي على 6 أشرطة )10 أقراص / شريط(.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة الشرق األوسط للصناعات الدوائية المحدودة. )أفالون فارما( ص.ب. 4180 الرياض 11491 المدينة الصناعية الثانية، الرياض، المملكة العربية السعودية هاتف 3427 265 &ndash; 3948 265 )11( 966 00 فاكس 4723 265 )11( 966 0</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة في 01-2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Quenfil 200 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 200 mg of Hydroxychloroquine Sulfate.
Excipients with known effect: Each film-coated tablet contains 36.50mg lactose monohydrate.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film coated tablet
Quenfil 200 mg film-coated tablets are White, round shaped biconvex filmcoated tabletplain 
on both sides.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adults Treatment of rheumatoid arthritis, discoid and systemic lupus erythematosus, and dermatological conditions caused or aggravated by sunlight. Paediatric population Treatment of juvenile idiopathic arthritis (in combination with other therapies), discoid and systemic lupus erythematosus.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology Adults (including the elderly) The minimum effective dose should be employed. This dose should not exceed 6.5 mg/kg/day (calculated from ideal body weight and not actual body weight) and will be either 200 mg or 400 mg per day. The 400 mg tablet should not be used in adults with an ideal body weight of less than 62kg. Pediatrics population The minimum effective dose should be employed and should not exceed 6.5 mg/kg/day based on ideal body weight. The 200 mg tablet is therefore not suitable for use in children with an ideal body weight of less than 31 kg. Method of administration: The tablets are for oral administration. 2 Each dose should be taken with a meal or glass of milk. Hydroxychloroquine is cumulative in action and will require several weeks to exert its beneficial effects, whereas minor side effects may occur relatively early. For rheumatic disease treatment should be discontinued if there is no improvement by 6 months. In light-sensitive diseases, treatment should only be given during periods of maximum exposure to light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                - Known hypersensitivity to 4-aminoquinoline compounds or to any of the excipients
listed in section 6.1.
- Pre-existing maculopathy of the eye.
- Below 6 years of age (200mg tablets not adapted for weight <35kg) or for ideal body
weight < 31 kg (see section 4.2)
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Retinopathy &bull; All patients should have an ophthalmological examination before initiating treatment with Quenfil. Thereafter, ophthalmological examinations must be repeated at least every 12 months. &bull; Retinal toxicity is largely dose-related. The risk of retinal damage is small with daily doses of up to 6.5 mg/kg body weight. Exceeding the recommended dose sharply increases the risk of retinal toxicity. The examination should include testing visual acuity and colour vision, careful ophthalmoscopy, fundoscopy and central visual field testing with a red target. This examination should be more frequent and adapted to the patient in the following situations: - daily dosage exceeds 6.5 mg/kg lean body weight. Absolute body weight used as a guide to dosage could result in an overdose in the obese. - renal insufficiency. - visual acuity below 6/8. - age above 65 years. - cumulative dose more than 200 g. Quenfil should be discontinued immediately in any patient who develops a pigmentary abnormality, visual field defect or any other abnormalities not explained by difficulty in accommodation (see also section 4.8). Patients should continue to be observed as retinal changes and visual disturbances may progress even after cessation of therapy (see also section 4.8). Concomitant use of hydroxychloroquine with medicines known to induce retinal toxicity, such as tamoxifen, is not recommended. 3 Hypoglycaemia Hydroxychloroquine has been shown to cause severe hypoglycaemia including loss of consciousness that could be life threatening in patients treated with and without antidiabetic medications. Patients treated with hydroxychloroquine should be warned about the risk of hypoglycaemia and the associated clinical signs and symptoms. Patients presenting with clinical symptoms suggestive of hypoglycaemia during treatment with hydroxychloroquine should have their blood glucose level checked and treatment reviewed as necessary. QT interval prolongation Hydroxychloroquine has the potential to prolong the QTc interval in patients with specific risks factors. Hydroxychloroquine should be used with caution in patients with congenital or documented acquired QT prolongation and/or known risk factors for prolongation of the QT interval such as: - cardiac disease, e.g., heart failure, myocardial infarction - proarrhythmic conditions, e.g., bradycardia (&lt; 50 bpm) - a history of ventricular dysrhythmias - uncorrected hypokalemia and/or hypomagnesemia - during concomitant administration with QT interval prolonging agents (see section 4.5) as this may lead to an increased risk for ventricular arrhythmias. The magnitude of QT prolongation may increase with increasing concentrations of the drug. Therefore, the recommended dose should not be exceeded (see also sections 4.5 and 4.8). If signs of cardiac arrhythmia occur during treatment with hydroxychloroquine, treatment should be stopped and an ECG should be performed. Chronic cardiac toxicity Cases of cardiomyopathy resulting in cardiac failure, in some cases with fatal outcome, have been reported in patients treated with hydroxychloroquine sulfate (see sections 4.8 and 4.9). Clinical monitoring for signs and symptoms of cardiomyopathy is advised and hydroxychloroquine sulfate should be discontinued if cardiomyopathy develops. Chronic toxicity should be considered when conduction disorders (bundle branch block/atrioventricular heart block) as well as biventricular hypertrophy are diagnosed (see section 4.8). Severe cutaneous adverse reactions (SCARs) Cases of severe cutaneous adverse drug reactions (SCARs), including drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP), Stevens- Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported during treatment with hydroxychloroquine. Patients with serious dermatological reactions may require hospitalization, as these conditions may be life-threatening and may be fatal. If signs and symptoms suggestive of severe skin reactions appear, hydroxychloroquine should be withdrawn at once and alternative therapy should be considered. Other precautions: Quenfil should be used with caution in patients taking medicines which may cause adverse 4 ocular or skin reactions. Caution should also be applied when it is used in the following: &bull; patients with hepatic or renal disease, and in those taking drugs known to affect those organs. Estimation of plasma hydroxychloroquine levels should be undertaken in patients with severely compromised renal or hepatic function and dosage adjusted accordingly. &bull; patients with severe gastrointestinal, neurological or blood disorders. Caution is also advised in patients with a sensitivity to quinine, those with glucose-6-phosphate dehydrogenase deficiency, those with porphyria cutanea tarda which can be exacerbated by hydroxychloroquine, and in patients with psoriasis since it appears to increase the risk of skin reactions. Small children are particularly sensitive to the toxic effects of 4-aminoquinolines; therefore, patients should be warned to keep Quenfil out of the reach of children. Other monitoring on long-term treatments Patients on long-term therapy should have periodic full blood counts, and hydroxychloroquine should be discontinued if abnormalities develop (see section 4.8). All patients on long-term therapy should undergo periodic examination of skeletal muscle function and tendon reflexes. If weakness occurs, the drug should be withdrawn (see section 4.8). Potential carcinogenic risk Animal carcinogenicity data are only available for one species for the parent drug chloroquine and this study was negative (see section 5.3). In humans, there are insufficient data to rule out an increased risk of cancer in patients receiving long-term treatment. Suicidal behaviour and psychiatric disorders Suicidal behaviour and psychiatric disorders have been reported in some patients treated with hydroxychloroquine (see section 4.8). Psychiatric side effects typically occur within the first month after the start of treatment with hydroxychloroquine and have been reported also in patients with no prior history of psychiatric disorders. Patients should be advised to seek medical advice promptly if they experience psychiatric symptoms during treatment. Extrapyramidal disorders Extrapyramidal disorders may occur with Quenfil (see section 4.8). Quenfil contains lactose monohydrate Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacodynamic interactions Medicines known to prolong QT interval / with potential to induce cardiac arrhythmia: Hydroxychloroquine should be used with caution in patients receiving medicines known to prolong the QT interval, e.g., Class IA and III antiarrhythmics, tricyclic antidepressants, antipsychotics, some anti-infectives (antibacterials such as fluoroquinolones e.g. moxifloxacin, macrolides e.g. azithromycin, antiretrovirals such as saquinavir, antifungals such as fluconazole, antiparasitic medicines such as pentamidine) due to increased risk of ventricular arrhythmia (see sections 4.4, 4.8 and 4.9). Halofantrine should not be administered with hydroxychloroquine. 5 As hydroxychloroquine may enhance the effects of a hypoglycaemic treatment, a decrease in doses of insulin or antidiabetic medicines may be required (see also section 4.4 &ldquo;Hypoglycaemia&rdquo; and section 4.8). Administration of hydroxychloroquine with antimalarials known to lower the convulsion threshold (e.g. mefloquine) may increase the risk of convulsions (see section 4.8). The activity of antiepileptic medicines might be impaired if co-administered with hydroxychloroquine. Concurrent use with medicines with oculotoxic potential (see also 4.4 &ldquo;retinopathy&rdquo;) or haemotoxic potential should be avoided if possible, because of potential additive effect (see section 4.8). There is a theoretical risk of inhibition of intra-cellular &alpha;-galactosidase activity when hydroxychloroquine is co-administered with agalsidase. Hydroxychloroquine sulphate may also be subject to several of the known interactions of chloroquine even though specific reports have not appeared. These include: potentiation of its direct blocking action at the neuromuscular junction by aminoglycoside antibiotics; antagonism of effect of neostigmine and pyridostigmine; reduction of the antibody response to primary immunization with intradermal human diploid-cell rabies vaccine. Pharmacokinetic interactions Effects of other medicinal products on hydroxychloroquine: Antacids and kaolin Concomitant administration with magnesium-containing antacids or kaolin may result in reduced absorption of chloroquine. Per extrapolation, hydroxychloroquine should therefore be administered at least two hours apart from antacids or kaolin. CYP inhibitors or inducers In vitro, hydroxychloroquine is metabolized mainly by CYP2C8, CYP3A4 and CYP2D6, with no major involvement of a single CYP. Concomitant use of cimetidine, a CYP-pan inhibitor, resulted in a 2-fold increase of chloroquine exposure. In the absence of in vivo drug interaction studies, caution is advised (e.g. monitoring for adverse reactions) when cimetidine or CYP2C8 and or CYP3A4 or CYP2D6 strong or inhibitors (such as gemfibrozil, clopidogrel, ritonavir, itraconazole, clarithromycin, grapefruit juice, fluoxetine, paroxetine, quinidine) are concomitantly administered. Lack of efficacy of hydroxychloroquine was reported when rifampicin, a CYP2C8 and CYP3A4 strong inducer, was concomitantly administered. Caution is advised (e.g. monitoring for efficacy) when CYP2C8 and/or CYP3A4 strong inducers (such as rifampicin, St John&#39;s Wort, carbamazepine, phenobarbital, phenytoin) are concomitantly administered. Effects of hydroxychloroquine on other medicinal products: P-glycoprotein substrates 6 Hydroxychloroquine inhibits P-gp in vitro at high concentrations.. Therefore, there is a potential for increased concentrations of P-gp substrates when hydroxychloroquine is concomitantly administered. Increased digoxin serum levels were reported when digoxin and hydroxychloroquine were coadministered. Caution is advised (e.g. monitoring for adverse reactions or for plasma concentrations as appropriate) when P-gp substrates with narrow therapeutic index (such as digoxin, dabigatran) are concomitantly administered. CYP2D6 substrates Hydroxychloroquine inhibits CYP2D6 in vitro. In patients receiving hydroxychloroquine and a single dose of metoprolol, a CYP2D6 probe, the Cmax and AUC of metoprolol were increased by 1.7-fold, which suggests that hydroxychloroquine is a mild inhibitor of CYP2D6. Caution is advised (e.g. monitoring for adverse reactions or for plasma concentrations as appropriate) when CYP2D6 substrates with narrow therapeutic index (such as such as flecainide, propafenone) are concomitantly administered. CYP3A4 substrates Hydroxychloroquine inhibits CYP3A4 in vitro. An increased plasma level of ciclosporin (a CYP3A4 and p-gp substrate) was reported when ciclosporin and hydroxychloroquine were co-administered. In the absence of in vivo interaction studies with sensitive CYP3A4 substrates, caution is advised (e.g. monitoring for adverse reactions) when CYP3A4 substrates (such as ciclosporin, statins) are concomitantly administered with hydroxychloroquine . Praziquantel In a single-dose interaction study, chloroquine has been reported to reduce the bioavailability of praziquantel. It is not known if there is a similar effect when hydroxychloroquine and praziquantel are coadministered. Per extrapolation, due to the similarities in structure and pharmacokinetic parameters between hydroxychloroquine and chloroquine, a similar effect may be expected for hydroxychloroquine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy A moderate amount of data in pregnant women (between 300-1000 prospective pregnancies) from observational studies, as well as a meta-analysis with high and long-term exposure (mainly in the indication autoimmune disease) do not show a statistically significant increased risk of congenital malformations or feto/neonatal toxicity related to hydroxychloroquine. Animal studies with the structurally related chloroquine, have shown reproduction toxicity at high maternal exposure (see section 5.3). In humans, hydroxychloroquine crosses the placenta and blood concentrations in the foetus are similar to maternal blood concentrations. Hydroxychloroquine sulfate should be avoided in pregnancy except when, in the judgement of the physician, the individual potential benefits outweigh the potential hazards. If treatment with hydroxychloroquine is necessary during pregnancy, the lowest effective dose should be used. In case of prolonged treatment during pregnancy, hydroxychloroquine safety profile in particular ophthalmological side effects should be taken into account for child monitoring. Fertility Animal studies showed an impairment of male fertility for chloroquine (see section 5.3). There are no data on the effects of hydroxychloroquine on fertility in humans. Lactation: Hydroxychloroquine is excreted in breast milk (less than 2% of the maternal dose after 7 bodyweight correction). Careful consideration should be given to long term treatment with hydroxychloroquine during lactation because of the slow elimination rate and the potential for accumulation of a toxic amount in the infant. It is known that infants are extremely sensitive to the toxic effects of 4- aminoquinolines. There are very limited data on the safety in the breastfed infant during hydroxychloroquine longterm treatment; the prescriber should assess the potential risks and benefits of use during breastfeeding, according to indication and duration of treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Impaired visual accommodation soon after the start of treatment, which can cause blurring of vision, has been reported and patients should be warned regarding driving or operating machinery. If the condition is not self-limiting it will resolve on reducing the dose or stopping treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.8.1: adverse reactions: The following CIOMS frequency rating is used, when applicable: Very common (&ge; 1/10), Common (&ge; 1/100 to &lt;1/10), Uncommon (&ge; 1/1,000 to &lt;1/100), Rare (&ge; 1/10,000 to &lt;1/1,000), Very rare (&lt;1/10,000), not known (cannot be estimated from the available data). Very common Common Uncommon Rare Very rare Not known Blood and Bone marrow lymphatic depression, anemia, system aplastic anemia, disorders agranulocytosis, leucopenia, thrombocytopenia. Immune system disorders Urticaria, angioedema, bronchospasm Metabolism and Anorexia Hypoglycemia nutrition Hydroxychloroquine disorders may exacerbate porphyria Psychiatric Affect Nervousness Psychosis, suicidal disorders lability behaviour, depression, hallucinations, anxiety, agitation, confusion, delusions, mania and sleep disorders. Nervous Headache Dizziness Convulsions have system been reported with disorders this class of medicines. Extrapyramidal disorders such as dystonia, dyskinesia, tremor (see section 4.4). Eye Blurring of Retinopathy, with Cases of disorders vision due changes In maculopathies and to a pigmentation and macular degeneration visual field defects. have been reported 8 Disturbance of accommod ation which is dose dependent and reversible In its early form, it appears reversible on discontinuation of hydroxychloroquine. If allowed to develop, there may be a risk of progression even after treatment withdrawal. Patients with retinal changes may be asymptomatic initially, or may have scotomatous vision with paracentral, pericentral ring types, temporal scotomas and abnormal colour vision. Corneal changes including edema and opacities have been reported. They are either symptomless or may cause disturbances such as halos , blurring of vision, or photophobia. They may be transient or are reversible on stopping treatment. and may be irreversible. Ear and labyrinth disorders Vertigo, tinnitus Hearing loss Cardiac Disorders QT interval prolongation in patients with specific risk factors, which may lead to arrhythmia (torsade de pointes, ventricular tachycardia) Cardiomyopathy which may result in cardiac failure and in some cases a fatal outcome (see Section 4.4 and Section 4.9). Chronic toxicity should be considered when conduction disorders (bundle branch block / atrioventricular heart block) as well as biventricular hypertrophy are found. 9 Hydroxychloroquine withdrawal may lead to recovery. Gastrointestinal disorders Abdominal pain, nausea Diarrhoea, vomiting These symptoms usually resolve immediately on reducing the dose or on stopping the treatment. Hepatobiliary disorders Abnormal liver function tests Fulminant hepatic failure Skin and subcutaneous tissue disorders Skin rash, pruritus Pigmentation disorders in skin and mucous membranes, bleaching of hair, alopecia These usually resolve readily on stopping treatment. Erythema multiforme, photosensitivity, exfoliative dermatitis, Sweet&rsquo;s syndrome and Severe cutaneous adverse reactions (SCARs) including Stevens - Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), Drug Rash with Eosinophilia and Systemic Symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP) (see section 4.4). AGEP has to be Distinguished from psoriasis, although Hydroxychloroquine may precipitate attacks of psoriasis. It may be associated with fever and hyperleukocytosi. Outcome is usually favourable after Hydroxychloroquine withdrawal. Musculoskeletal and connective tissue disorders Sensorimotor disorders Skeletal muscle myopathy or neuromyopathy leading to progressive weakness and atrophy of proximal muscle groups. Myopathy may be reversible after hydroxychloroquine discontinuation, but 1 recovery may take many months. Depression of tendon reflexes and abnormal nerve conduction studies</p><p>To Report any side effects: Saudi Arabia:The National Pharmacovigilance Centre (NPC) o SFDA call center: 19999 o E-mail: npc.drug@sfda.gov.sa o Website: https://ade.sfda.gov.sa</p><p>Other GCC States:- Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdosage with the 4-aminoquinolines is dangerous particularly in infants, as little as 1-2g having proved fatal. The symptoms of overdosage may include headache, visual disturbances, cardiovascular collapse, convulsions, hypokalaemia, rhythm and conduction disorders, including QT prolongation, torsade de pointes, ventricular tachycardia and ventricular fibrillation, widthincreased QRS complex, bradyarrhythmias, nodal rhythm, atrioventricular block,, followed by sudden and potentially fatal respiratory and cardiac arrest. Immediate medical attention is required, as these effects may appear shortly after the overdose. The stomach should be immediately evacuated, either by emesis or by gastric lavage. Activated charcoal in a dose at least five times that of the overdosage may inhibit further absorption if introduced into the stomach by tube, following lavage, and within 30 minutes of ingestion of the overdose. Consideration should be given to administration of parenteral diazepam in cases of overdosage; it has been shown to be beneficial in reversing chloroquine cardiotoxicity. Respiratory support and shock management should be instituted as necessary.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Antimalarial agents like chloroquine and hydroxychloroquine have several pharmacological actions which may be involved in their therapeutic effect in the treatment of rheumatic disease, but the role of each is not known. These include interaction with sulphydryl groups, interference with enzyme activity (including phospholipase, NADH - cytochrome C reductase, cholinesterase, proteases and hydrolases), DNA binding, stabilisation of lysosomal membranes, inhibition of prostaglandin formation, inhibition of polymorphonuclear cell chemotaxis and The National Pharmacovigilance Centre (NPC) o SFDA call center: 19999 o E-mail: npc.drug@sfda.gov.sa o Website: https://ade.sfda.gov.sa - Please contact the relevant competent authority 1 phagocytosis, possible interference with interleukin 1 production from monocytes and inhibition of neutrophil superoxide release.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption Following oral administration, peak plasma or blood concentrations is achieved in approximately 3 to 4 hours. Mean absolute oral bioavailability is 79% (SD 12%) in fasting conditions. Food does not modify the oral bioavailability of hydroxychloroquine. Distribution Hydroxychloroquine has a large volume of distribution (5500 L when assessed from blood concentrations, 44 000 L when assessed from plasma concentrations), due to extensive tissue accumulation (such as eyes, kidney, liver and lungs) and has been shown to accumulate in blood cells, with a blood to plasma ratio of 7.2. Approximately 50% of hydroxychloroquine is bound to plasma proteins. Biotransformation Hydroxychloroquine is mainly metabolized to N-desethylhydroxychloroquine, and two other metabolites in common with chloroquine, desethylchloroquine and bidesethylchloroquine. In vitro, hydroxychloroquine is metabolized mainly by CYP2C8, CYP3A4 and CYP2D6 as well as by FMO-1 and MAO-A, with no major involvement of a single CYP or enzyme. Elimination Hydroxychloroquine presents a multi-phasic elimination profile with a long terminal half-life ranging from 30 to 50 days. Approximately 20-25% of the hydroxychloroquine dose is eliminated as unchanged product in the urine. After chronic repeated oral administration of 200 mg and 400 mg hydroxychloroquine sulfate once a day in adult patients with lupus or rheumatoid arthritis, the average steady-state concentrations were around 450-490 ng/mL and 870-970 ng/mL in blood, respectively. The pharmacokinetics of hydroxychloroquine appears to be linear in the therapeutic dose range of 200 to 500 mg/day. Pharmacokinetic interactions Effect of hydroxychloroquine on other medicinal products In vitro, hydroxychloroquine has no potential to inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9 and CYP2C19. Hydroxychloroquine inhibits CYP2D6 and CYP3A4 in vitro. An interaction study has shown that hydroxychloroquine is a mild inhibitor of CYP2D6 (see section 4.5). In vitro, hydroxychloroquine has no significant potential to induce CYP1A2, CYP2B6 and CYP3A4. In vitro, hydroxychloroquine did not significantly inhibit the main transporters BCRP, OATP1B1, OATP1B3, OAT1 and OAT3. Hydroxychloroquine inhibited P-gp at high concentrations (see section 4.5). In vitro, hydroxychloroquine has a potential to inhibit OCT1, OCT2, MATE1 and MATE2-K transporters. Renal impairment Renal impairment is not expected to significantly modify the pharmacokinetics of hydroxychloroquine in patients with renal impairment because hydroxychloroquine is mainly metabolized and only 20-25% of the hydroxychloroquine dose is eliminated as unchanged drug in the urine. Hydroxychloroquine exposure can increase by up to 46% in patients with moderate and severe renal impairment (see section 4.4). 1 Hepatic impairment The effect of hepatic impairment on hydroxychloroquine pharmacokinetics has not been evaluated in a specific PK study. Given that hydroxychloroquine is mainly metabolized, hydroxychloroquine exposure is expected to increase in patients with hepatic impairment (see section 4.4). Elderly The limited data available in elderly rheumatoid arthritis patients suggest that hydroxychloroquine exposures remain in the same range as those observed in younger patients. Paediatrics The pharmacokinetics of hydroxychloroquine in children aged below 18 years of age have not been established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Genotoxicity/Carcinogenicity Based on the studies conducted, hydroxychloroquine is not found to be genotoxic. No relevant nonclinical carcinogenicity studies on hydroxychloroquine are available. Reproductive and developmental toxicity Hydroxychloroquine crosses the placenta. In non-GLP studies with mice and monkeys, transplacental transfer chloroquine, a substance related to hydroxychloroquine, was demonstrated with accumulation in foetal eye and ear tissue. High maternal doses of chloroquine were foetotoxic in rats and caused anophthalmia and microphthalmia. In studies in rats, chloroquine reduced the testosterone secretion, the weight of the testis and epididymis and caused production of abnormal sperm. There are no preclinical safety data of relevance to the prescriber, which are additional to that already included in other sections of the SPC.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hydroxychloroquine Sulfate Lactose monohydrate (Pharmatose 200) Maize starch Povidone K 30 (Kollidone k 30) Magnesium Stearate (Parteck LUB MST) Opadry White (OY-L-28900)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 Months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clear Alu-PVC/PVDC 250 &mu;m/60 GSM blister packs of 60 film-coated tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Middle East Pharmaceutical Industries Co. Ltd (Avalon-Pharma)
2nd industrial City, P.O.Box 4180 Riyadh 11491, Kingdom of Saudi Arabia
Tel: 920010564, Fax: +966 (11) 2654723
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                05/2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>